ArticleMolecular oncology2014

N-terminal targeting of androgen receptor variant enhances response of castration resistant prostate cancer to taxane chemotherapy.

Sarah K Martin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.